Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Tyro3 is a podocyte protective factor in glomerular disease
Fang Zhong, Zhaohong Chen, Liwen Zhang, Yifan Xie, Viji Nair, Wenjun Ju, Matthias Kretzler, Robert G. Nelson, Zhengzhe Li, Hongyu Chen, Yongjun Wang, Aihua Zhang, Kyung Lee, Zhihong Liu, John Cijiang He
Fang Zhong, Zhaohong Chen, Liwen Zhang, Yifan Xie, Viji Nair, Wenjun Ju, Matthias Kretzler, Robert G. Nelson, Zhengzhe Li, Hongyu Chen, Yongjun Wang, Aihua Zhang, Kyung Lee, Zhihong Liu, John Cijiang He
View: Text | PDF
Research Article Nephrology

Tyro3 is a podocyte protective factor in glomerular disease

  • Text
  • PDF
Abstract

Our previous work demonstrated a protective role of protein S in early diabetic kidney disease (DKD). Protein S exerts antiinflammatory and antiapoptotic effects through the activation of TYRO3, AXL, and MER (TAM) receptors. Among the 3 TAM receptors, we showed that the biological effects of protein S were mediated largely by TYRO3 in diabetic kidneys. Our data now show that TYRO3 mRNA expression is highly enriched in human glomeruli and that TYRO3 protein is expressed in podocytes. Interestingly, glomerular TYRO3 mRNA expression increased in mild DKD but was suppressed in progressive DKD, as well as in focal segmental glomerulosclerosis (FSGS). Functionally, morpholino-mediated knockdown of tyro3 altered glomerular filtration barrier development in zebrafish larvae, and genetic ablation of Tyro3 in murine models of DKD and Adriamycin-induced nephropathy (ADRN) worsened albuminuria and glomerular injury. Conversely, the induction of TYRO3 overexpression specifically in podocytes significantly attenuated albuminuria and kidney injury in mice with DKD, ADRN, and HIV-associated nephropathy (HIVAN). Mechanistically, TYRO3 expression was suppressed by activation of TNF-α/NF-κB pathway, which may contribute to decreased TYRO3 expression in progressive DKD and FSGS, and TYRO3 signaling conferred antiapoptotic effects through the activation of AKT in podocytes. In conclusion, TYRO3 plays a critical role in maintaining normal podocyte function and may be a potential new drug target to treat glomerular diseases.

Authors

Fang Zhong, Zhaohong Chen, Liwen Zhang, Yifan Xie, Viji Nair, Wenjun Ju, Matthias Kretzler, Robert G. Nelson, Zhengzhe Li, Hongyu Chen, Yongjun Wang, Aihua Zhang, Kyung Lee, Zhihong Liu, John Cijiang He

×

Figure 10

TYRO3 signaling affects AKT activation in cultured podocytes.

Options: View larger image (or click on image) Download as PowerPoint
TYRO3 signaling affects AKT activation in cultured podocytes.
(A) Real-t...
(A) Real-time PCR analysis of TYRO3 mRNA in cultured human podocytes after TNF-α treatment (10 ng/ml) for 6 hours with or without pretreatment with NF-κB inhibitor BAY11-7082 (BAY, 5 μM) for 1 hour. n = 3 per sample; 2-tailed, unpaired t test was performed to compare means between groups. ***P < 0.001 when compared with DMSO control, ##P < 0.01 when compared with TNF-α. (B) Western blot analysis of TYRO3 in cells in A. (C) Western blot analysis of total and phosphorylated AKT in cultured podocytes with Tyro3 overexpression (Tyro3OV) or Tyro3 knockdown (Tyro3KD) compared with control knockdown (ControlKD) podocytes. (D and E) Annexin V analysis of apoptosis in ControlKD and Tyro3KD podocytes. FACS analysis is shown in D, and quantification is shown in E. n = 4 per sample; 2-tailed, unpaired t test was performed to compare means between groups. ***P < 0.001 when compared with ControlKD. (F) Active Caspase-3 concentration in cultured podocytes (WT, Tyro3ov, or Tyro3KD) under normal (control), high mannitol (mannitol), or high glucose (glucose) conditions. n = 5; 1-way ANOVA with Tukey’s multiple comparison test was performed to compare means. ****P < 0.0001 when compared with control group; ##P < 0.01 and ####P < 0.0001 when compared with glucose group. (G) Active Caspase-3 concentration in cultured podocytes under normal (control), high mannitol (mannitol), or high glucose (glucose) conditions with or without protein S (PS; 50 nM) and AKT inhibitor (AKTi; 1 μM). n = 5; 1-way ANOVA with Tukey’s multiple comparison test was performed to compare means. ****P < 0.0001 when compared with control group; ##P < 0.01 when compared with glucose group; §§§§P < 0.0001 when compared with glucose+PS group.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts